David Andrew Arlwydd Owen
Directeur/Membre du Conseil chez Oxford Gene Technology IP Ltd.
Profil
David Andrew Arlwydd Owen is the founder of MVM Ltd.
He currently holds director positions at Oxford Gene Technology IP Ltd.
and Oxford Gene Technology (Operations) Ltd.
He previously held director positions at Ardana Plc, Cobra Therapeutics Ltd., RiboTargets Ltd., Prolifix Ltd., Imaxio SA, and Elara Pharmaceuticals GmbH.
He also served as Group Director-Compound & Technology Acquisitions at SmithKline & French SpA and as Non-Executive Chairman at AERES Biomedical Ltd.
Postes actifs de David Andrew Arlwydd Owen
| Sociétés | Poste | Début |
|---|---|---|
Oxford Gene Technology IP Ltd.
 Oxford Gene Technology IP Ltd. BiotechnologyHealth Technology Part of Sysmex Corp., Oxford Gene Technology IP Ltd. is a British company that engages in research and experimental development on biotechnology. The company is based in Begbroke, UK. | Directeur/Membre du Conseil | - |
Oxford Gene Technology (Operations) Ltd.
 Oxford Gene Technology (Operations) Ltd. Pharmaceuticals: MajorHealth Technology Part of Sysmex Corp., Oxford Gene Technology (Operations) Ltd. is a holding British company that operates subsidiaries which develop, manufacture, and market molecular genetics. The company is based in Begbroke, UK and was founded in 1999. | Directeur/Membre du Conseil | 07/09/2005 |
Anciens postes connus de David Andrew Arlwydd Owen
| Sociétés | Poste | Fin |
|---|---|---|
Cobra Therapeutics Ltd.
 Cobra Therapeutics Ltd. Medical SpecialtiesHealth Technology Cobra Therapeutics Ltd. manufactured cancer therapeutics on contract basis. It also developed gene delivery and expression technologies. The company was founded in 1992 and was headquartered in Keele, UK | Directeur/Membre du Conseil | 12/11/2007 |
| RiboTargets Ltd. | Directeur/Membre du Conseil | 12/11/2007 |
MVM Ltd.
 MVM Ltd. Gas DistributorsUtilities MVM Ltd. distributes natural gas and electricity. | Fondateur | - |
Elara Pharmaceuticals GmbH
 Elara Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Elara Pharmaceuticals GmbH focuses on the development of novel treatments for malignant diseases. It has developed three distinct and proprietary dual mechanism chemotypes that potently inhibit the HIF signaling pathway and induce apoptosis. The firm has identified compounds with excellent in vitro activity against a diverse set of tumor cell lines and superior pharmacokinetic and toxicity profiles in vivo. The company was founded by Frank Gannon, Joe D. Lewis and George Reid on July 27, 2006 and is headquartered in Heidelberg, Germany. | Directeur/Membre du Conseil | - |
MVM Partners LLP
 MVM Partners LLP Investment ManagersFinance MVM Partners LLP (MVM Partners) is a venture capital firm founded in 1997. The firm is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 12 |
|---|---|
Ardana Plc
 Ardana Plc Pharmaceuticals: MajorHealth Technology Ardana Plc developed pharmaceuticals products. It offered Invicorp, an intracavernosal injectable combination of phentolamine mesilate and vasoactive intestinal polypeptide for the treatment of male erectile dysfunction. The company was founded in 2000 and was headquartered in Bristol, the United Kingdom. | Health Technology |
MVM Partners LLP
MVM Partners LLP Investment ManagersFinance MVM Partners LLP (MVM Partners) is a venture capital firm founded in 1997. The firm is headquartered in London, the United Kingdom. | Finance |
Cobra Therapeutics Ltd.
Cobra Therapeutics Ltd. Medical SpecialtiesHealth Technology Cobra Therapeutics Ltd. manufactured cancer therapeutics on contract basis. It also developed gene delivery and expression technologies. The company was founded in 1992 and was headquartered in Keele, UK | Health Technology |
| RiboTargets Ltd. | Health Technology |
SmithKline & French SpA
 SmithKline & French SpA Pharmaceuticals: MajorHealth Technology Part of Procter & Gamble Co., SmithKline & French SpA is a pharmaceutical concern. SmithKline & French was acquired by Procter & Gamble Co. from Smithkline Beecham Plc on September 29, 1993. | Health Technology |
| Prolifix Ltd. | Commercial Services |
AERES Biomedical Ltd.
 AERES Biomedical Ltd. Drugstore ChainsRetail Trade AERES Biomedical Ltd. develops therapeutic antibodies. The firm's products target debilitating and life-threatening illnesses, such as infectious, inflamatory and cardiovascular diseases. The company was founded on July 5, 1999 by Tarran Jones & David Copsey and is headquartered in Mill Hill, the United Kingdom. | Retail Trade |
Imaxio SA
 Imaxio SA Medical SpecialtiesHealth Technology Imaxio SA develops biopharmaceutical products. It operates as a biotech company which focuses on vaccines, and based on the combination of commercial and research and development activities. The firm provides its services based on proprietary and Agilent DNA chips, notably CGH micro-array analyses. The company was founded by Christian Pradeyrol and Jean Chatellier in 2000 and is headquartered in Lyon, France. | Health Technology |
MVM Ltd.
MVM Ltd. Gas DistributorsUtilities MVM Ltd. distributes natural gas and electricity. | Utilities |
Oxford Gene Technology (Operations) Ltd.
Oxford Gene Technology (Operations) Ltd. Pharmaceuticals: MajorHealth Technology Part of Sysmex Corp., Oxford Gene Technology (Operations) Ltd. is a holding British company that operates subsidiaries which develop, manufacture, and market molecular genetics. The company is based in Begbroke, UK and was founded in 1999. | Health Technology |
Elara Pharmaceuticals GmbH
Elara Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Elara Pharmaceuticals GmbH focuses on the development of novel treatments for malignant diseases. It has developed three distinct and proprietary dual mechanism chemotypes that potently inhibit the HIF signaling pathway and induce apoptosis. The firm has identified compounds with excellent in vitro activity against a diverse set of tumor cell lines and superior pharmacokinetic and toxicity profiles in vivo. The company was founded by Frank Gannon, Joe D. Lewis and George Reid on July 27, 2006 and is headquartered in Heidelberg, Germany. | Health Technology |
Oxford Gene Technology IP Ltd.
Oxford Gene Technology IP Ltd. BiotechnologyHealth Technology Part of Sysmex Corp., Oxford Gene Technology IP Ltd. is a British company that engages in research and experimental development on biotechnology. The company is based in Begbroke, UK. | Health Technology |
